HEALTH CARE COMPARATIVE EFFECTIVENESS IN THE UNITED STATES
SYMPOSIUM
|
Sunday, May 20, 2007, 5:00 p.m. - 7:00 p.m.
Reception & Networking: 7:00 p.m. - 7:30 p.m.
Salon A & B
Crystal Gateway Marriott, Arlington, Virginia, USA
Prior to the ISPOR 12th Annual International Meeting
This symposium is co-Sponsored by ISPOR and PhRMA Health Outcomes
Committee
NO PRE-REGISTRATION REQUIRED
|
 SYMPOSIUM BACKGROUND
The advent of government conducted systematic reviews in the United States [Agency for Health Care Research and Quality (AHRQ) & the Drug Effectiveness Review Project (DERP) by 15 US State Medicaid agencies], Canada [Canadian Agency for Drugs & Technologies in Health (CADTH)] and Europe [United Kingdom’s National Institute for Clinical Effectiveness (NICE) and Germany’s German Institute for Quality and Efficiency in Health Care (IQWIG)] have direct consequences on how health outcome research will be conducted, translated and used in health care decisions.
The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, authorized AHRQ to address the issue of comparative effectiveness of health care treatments including drugs, medical devices, and diagnostics. AHRQ developed a priority of diseases to be addressed in this initiative. Eight comparative effectiveness reports have been issued.
This symposium will address 4 key questions concerning comparative effectiveness in the United States: 1) who should develop & fund comparative effectiveness information? 2) What should be the scope of comparative assessments, since less than 20% of health care expenditures in the US are for drugs, devices, and diagnostics? 3) How should this information be disseminated for timely, personalized health care decisions? and; 4) What is the ‘cost-effectiveness’ of these comparative effectiveness assessments?
|
|
PROGRAM- SUNDAY, MAY 20, 2007 |
| |
Moderator: J. Michael Woolley PhD,
Director, Global Health Economics, Amgen Inc.,
Thousand Oaks, CA, USA
|
| 5:00 - 5:10 |
Comparative Effectiveness in
the US: An Overview |
| |
Speaker: Kim Gilchrist MD,
Executive Director, Health Economics & Outcomes
Research, AstraZeneca. LP, Wilmington, DE, USA
Randomized controlled trials for regulatory approval have been traditional evidence requirements. Purchasers and insurers are requesting additional evidence between therapies for access and coverage. How do these needs align in the comparative effectiveness discussion?
|
| 5:10 - 5:35 |
A Comparative Effectiveness
Center: Is That What is Needed? |
| |
Speaker: Gail Wilensky PhD,
Economist, and Senior Fellow, Project HOPE,
Bethesda, MD, USA
In a recent article, "Developing A Center for Comparative Effectiveness Information" [Ref: Health Affairs, Nov/Dec 2006 25(6): w572-585], Dr. Wilensky emphasized that appropriate structure, placement, financing, and function of an agency devoted to comparative effectiveness in the US needs to be carefully considered, if it is to support better health care decision-making. Dr. Wilensky will explore options for placement of an agency. |
| 5:35 - 6:00 |
Comparative Effectiveness
Information & Health Care Delivery |
| |
Speaker: Carolyn Clancy, MD,
Director, Agency for Healthcare Research and
Quality, Rockville, MD, USA
In a recent article, "Getting to ‘Smart’ Health" [Ref: Health Affairs, Nov/Dec 2006 25(6): w589-592], Dr. Clancy stressed that the advances in biomedicine and information technology will provide timely, relevant information about comparative effectiveness, but transparency and private and public partnerships will be needed to support better health care decision-making. Dr. Clancy will explore these advances & essential themes for effective health care.
|
| 6:00 - 6:25 |
Comparative Effectiveness: Not
Just for Drugs |
| |
Speaker: Marc Berger MD, Vice
President, Global Health Outcomes, Eli Lilly,
Indianapolis, IN, USA
Comparative effectiveness analyses will increasingly influence access to new diagnostics, drugs, biologics, and devices. Developers need to know where “the goal posts will be” to design appropriate R&D strategies. Optimal health policy decision-making will be based upon a shared public-private responsibility to 1) generate and synthesize the evidence, and 2) establish methodological and evidence standards. These issues will be presented.
|
| 6:25 - 6:50 |
Evidence for Medicare Coverage:
Now and the Future |
| |
Speaker: Steve Phurrough MD, MPA,
Director, Coverage Analysis Group, Centers for
Medicare and Medicaid Services, Baltimore, MD
USA
Evidence for Medicare coverage has matured to embrace evidence-based medicine and will continue to evolve to encompass life-cycle evidence development.
|
| 6:50 - 7:00 |
Question & Answer |
12th Annual International Meeting Main Page
|
|
